ClinicalTrials.gg
Enrolling by invitationNCT07625956Pack2Pouch+Updated Nov 16, 2026

Piloting Novel Interventional Strategies to Improve Nicotine Pouches as a Substitute for Smoking

A Phase 4 interventional study of Nicotine replacement therapy patches and Oral nicotine pouches in Smoking ( Cigarette), sponsored by Medical University of South Carolina. Enrolling by invitation at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Medical University of South Carolina · Phase 4, Interventional, and Treatment

How we know

Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Cigarette Smoking by Medical University of South Carolina — 6 open to participants now, 6 under way, none of them phase 3. Cigarette Smoking · Medical University of South Carolina.

Planned enrollment
15th of 15
10 · median 99
Started
2026
the only one that year
Phase 4
Only one
of the 15
Registered
15th of 15
by date

Among the 15 studies in Cigarette Smoking by Medical University of South Carolina, this one is the 15th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 4, and was the 15th registered.

Cigarette Smoking

477 studies on the registry are indexed under Cigarette Smoking; 87 are open to participants now.

Browse Cigarette Smoking studies →

Open to participants now

6 of the 15 studies in Cigarette Smoking by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 62 Cigarette Smoking studies recruiting now, 38 (61%) set no upper age limit and 18 (29%) stop at 75 or younger; 1 takes children under 18; 33 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Cigarette Smoking by Medical University of South Carolina, or all of them as a file.
02

Study summary

Some people who smoke cigarettes try to switch to oral nicotine pouches but are not able to fully stop smoking. This study tests two new strategies for people who previously tried to switch using nicotine pouches. Participants who were unable to fully switch will either be asked to increase the nicotine strength of their pouches or to use a nicotine patch along with pouches. The goal of the study is to see whether these strategies are feasible, acceptable, and helpful, and to inform the design of larger future studies.

03

Conditions studied

  • Smoking ( Cigarette)

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 21 years or older
  • Currently enrolled in and completed the Pack2Pouch parent study
  • Current combustible tobacco smoking at extension study enrollment
  • Able to attend in-person visits in the Charleston, SC area
  • Access to internet and mobile communication

Exclusion criteria

Exclusion Criteria:

  • Pregnancy, breastfeeding, or nursing
  • Medical to nicotine replacement therapy
  • Current use of smoking cessation medications
  • Non-English proficiency
  • Use of other combustible tobacco or frequent non-combustible nicotine products outside study protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Increase

    Increase nicotine content of pouches

    Drug: Oral nicotine pouches

  • Active comparator
    Augment

    Add nicotine replacement therapy

    Drug: Nicotine replacement therapy patches

  • No intervention
    Continue

    Participants will continue with their treatment from the parent trial.

Interventions

  • DrugNicotine replacement therapy patches

    Nicotine replacement therapy patches will be dosed based on current cigarette smoking at the end of the parent trial.

  • DrugOral nicotine pouches

    Zyn oral nicotine pouches will be provided in the flavor preference of the participant and dosed based on their randomization in the parent trial and randomization in the extension study.

06

What researchers measure

Primary outcomes

  1. Feasibility

    Feasibility endpoints include 1) the proportion of eligible subjects who subsequently enroll; 2) the proportion of enrolled subjects who complete the Day 28 and Day 56 assessments; and 3) the proportion of enrolled subjects who complete ≥80% of their daily surveys during the switching period.

    Time frame: Days 1-56

  2. Acceptability

    Acceptability endpoints will be measured by the Acceptability of Intervention Measure (AIM). This measure includes 4 items rated on scale of 1 to 5. Scores are created by averaging responses, with values ranging from 1 to 5. Higher values indicate higher acceptability.

    Time frame: Day 28

07

Study locations

1 site
  • Medical Universtiy of South Carolina
    Charleston, South Carolina 29425, United States
08

References and documents

Individual participant data

Plan to share: Yes — Data from this study may be shared, by reasonable request, with other investigators not affiliated with the tobacco industry.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2026 (actual). Primary completion is estimated for Feb 2027, 8 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Feb 2027 and completion Oct 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartActual
Jun 26, 2026
Primary completionEst.
Feb 28, 2027was Oct 2026
CompletionEst.
Mar 31, 2027was Oct 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 2026→Feb 28, 2027
Nov 16, 2026
Study completion
Oct 2026→Mar 31, 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Oct 2026→Feb 28, 2027
    Study completion Oct 2026→Mar 31, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625956
Responsible party
Amanda Palmer (Research Assistant Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Jun 4, 2026
Start date
Jun 26, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Amanda Palmer, PhD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion